Loading stock data…
$0.78-0.05 (-5.89%)
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer.
KAPA in the Healthcare sector is trading at $0.78 with a market capitalization of $3M. Wall Street consensus targets $49.00 (2 analysts), implying a +6183.2% move over the next 12 months. The stock is currently near its 52-week low of $0.74, remaining 76.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.42M↑ | -$1.69M↓ | -$1.42M↑ | -$1.44M↑ | -$1.46M |
| Net Income | -$1.39M↑ | -$1.65M↓ | -$1.36M↑ | -$1.40M↑ | -$1.42M |
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lu...